nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—CYP2A6—Ifosfamide—testicular cancer	0.33	0.554	CbGbCtD
Ezogabine—UGT1A1—Etoposide—testicular cancer	0.265	0.446	CbGbCtD
Ezogabine—Coma—Methotrexate—testicular cancer	0.00154	0.00379	CcSEcCtD
Ezogabine—Discomfort—Bleomycin—testicular cancer	0.00153	0.00378	CcSEcCtD
Ezogabine—Malaise—Dactinomycin—testicular cancer	0.00153	0.00378	CcSEcCtD
Ezogabine—Urinary tract disorder—Cisplatin—testicular cancer	0.00152	0.00375	CcSEcCtD
Ezogabine—Leukopenia—Dactinomycin—testicular cancer	0.00152	0.00375	CcSEcCtD
Ezogabine—Urethral disorder—Cisplatin—testicular cancer	0.00151	0.00373	CcSEcCtD
Ezogabine—Constipation—Vinblastine—testicular cancer	0.0015	0.00371	CcSEcCtD
Ezogabine—Confusional state—Bleomycin—testicular cancer	0.0015	0.0037	CcSEcCtD
Ezogabine—Gait disturbance—Doxorubicin—testicular cancer	0.00149	0.00368	CcSEcCtD
Ezogabine—Hepatobiliary disease—Etoposide—testicular cancer	0.00149	0.00367	CcSEcCtD
Ezogabine—Visual impairment—Cisplatin—testicular cancer	0.00148	0.00366	CcSEcCtD
Ezogabine—Coordination abnormal—Doxorubicin—testicular cancer	0.00148	0.00366	CcSEcCtD
Ezogabine—Infection—Bleomycin—testicular cancer	0.00147	0.00364	CcSEcCtD
Ezogabine—Vision blurred—Ifosfamide—testicular cancer	0.00146	0.00362	CcSEcCtD
Ezogabine—Thrombocytopenia—Bleomycin—testicular cancer	0.00145	0.00359	CcSEcCtD
Ezogabine—Feeling abnormal—Vinblastine—testicular cancer	0.00145	0.00358	CcSEcCtD
Ezogabine—Ill-defined disorder—Ifosfamide—testicular cancer	0.00144	0.00356	CcSEcCtD
Ezogabine—Eye disorder—Cisplatin—testicular cancer	0.00144	0.00355	CcSEcCtD
Ezogabine—Coma—Epirubicin—testicular cancer	0.00144	0.00355	CcSEcCtD
Ezogabine—Discomfort—Dactinomycin—testicular cancer	0.00143	0.00352	CcSEcCtD
Ezogabine—Malaise—Ifosfamide—testicular cancer	0.0014	0.00346	CcSEcCtD
Ezogabine—Vertigo—Ifosfamide—testicular cancer	0.0014	0.00345	CcSEcCtD
Ezogabine—Urinary tract disorder—Etoposide—testicular cancer	0.00139	0.00344	CcSEcCtD
Ezogabine—Leukopenia—Ifosfamide—testicular cancer	0.00139	0.00344	CcSEcCtD
Ezogabine—Urethral disorder—Etoposide—testicular cancer	0.00138	0.00341	CcSEcCtD
Ezogabine—Asthenia—Chlorambucil—testicular cancer	0.00138	0.0034	CcSEcCtD
Ezogabine—Infection—Dactinomycin—testicular cancer	0.00137	0.0034	CcSEcCtD
Ezogabine—Alopecia—Cisplatin—testicular cancer	0.00136	0.00336	CcSEcCtD
Ezogabine—Thrombocytopenia—Dactinomycin—testicular cancer	0.00135	0.00335	CcSEcCtD
Ezogabine—Malnutrition—Cisplatin—testicular cancer	0.00134	0.00331	CcSEcCtD
Ezogabine—Paraesthesia—Bleomycin—testicular cancer	0.00133	0.00329	CcSEcCtD
Ezogabine—Coma—Doxorubicin—testicular cancer	0.00133	0.00329	CcSEcCtD
Ezogabine—Dyspnoea—Bleomycin—testicular cancer	0.00132	0.00327	CcSEcCtD
Ezogabine—Eye disorder—Etoposide—testicular cancer	0.00132	0.00325	CcSEcCtD
Ezogabine—Discomfort—Ifosfamide—testicular cancer	0.00131	0.00323	CcSEcCtD
Ezogabine—Muscle spasms—Cisplatin—testicular cancer	0.00129	0.00318	CcSEcCtD
Ezogabine—Confusional state—Ifosfamide—testicular cancer	0.00128	0.00316	CcSEcCtD
Ezogabine—Vision blurred—Cisplatin—testicular cancer	0.00126	0.00312	CcSEcCtD
Ezogabine—Asthenia—Vinblastine—testicular cancer	0.00126	0.00311	CcSEcCtD
Ezogabine—Infection—Ifosfamide—testicular cancer	0.00126	0.00311	CcSEcCtD
Ezogabine—Tremor—Cisplatin—testicular cancer	0.00125	0.0031	CcSEcCtD
Ezogabine—Alopecia—Etoposide—testicular cancer	0.00125	0.00308	CcSEcCtD
Ezogabine—Nervous system disorder—Ifosfamide—testicular cancer	0.00124	0.00307	CcSEcCtD
Ezogabine—Ill-defined disorder—Cisplatin—testicular cancer	0.00124	0.00307	CcSEcCtD
Ezogabine—Thrombocytopenia—Ifosfamide—testicular cancer	0.00124	0.00307	CcSEcCtD
Ezogabine—Hyperhidrosis—Ifosfamide—testicular cancer	0.00123	0.00303	CcSEcCtD
Ezogabine—Feeling abnormal—Bleomycin—testicular cancer	0.00122	0.00302	CcSEcCtD
Ezogabine—Osteoarthritis—Methotrexate—testicular cancer	0.00122	0.00301	CcSEcCtD
Ezogabine—Increased appetite—Epirubicin—testicular cancer	0.00122	0.003	CcSEcCtD
Ezogabine—Malaise—Cisplatin—testicular cancer	0.00121	0.00298	CcSEcCtD
Ezogabine—Leukopenia—Cisplatin—testicular cancer	0.0012	0.00296	CcSEcCtD
Ezogabine—Fatigue—Dactinomycin—testicular cancer	0.00119	0.00295	CcSEcCtD
Ezogabine—Muscle spasms—Etoposide—testicular cancer	0.00118	0.00291	CcSEcCtD
Ezogabine—Dizziness—Vinblastine—testicular cancer	0.00116	0.00287	CcSEcCtD
Ezogabine—Diplopia—Epirubicin—testicular cancer	0.00114	0.00282	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—testicular cancer	0.00114	0.00282	CcSEcCtD
Ezogabine—Feeling abnormal—Dactinomycin—testicular cancer	0.00114	0.00282	CcSEcCtD
Ezogabine—Nausea—Chlorambucil—testicular cancer	0.00114	0.00281	CcSEcCtD
Ezogabine—Paraesthesia—Ifosfamide—testicular cancer	0.00114	0.00281	CcSEcCtD
Ezogabine—Ill-defined disorder—Etoposide—testicular cancer	0.00114	0.00281	CcSEcCtD
Ezogabine—Anxiety—Cisplatin—testicular cancer	0.00114	0.00281	CcSEcCtD
Ezogabine—Dyspnoea—Ifosfamide—testicular cancer	0.00113	0.00279	CcSEcCtD
Ezogabine—Somnolence—Ifosfamide—testicular cancer	0.00113	0.00278	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—testicular cancer	0.00113	0.00278	CcSEcCtD
Ezogabine—Discomfort—Cisplatin—testicular cancer	0.00113	0.00278	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—testicular cancer	0.00112	0.00278	CcSEcCtD
Ezogabine—Malaise—Etoposide—testicular cancer	0.00111	0.00273	CcSEcCtD
Ezogabine—Vertigo—Etoposide—testicular cancer	0.0011	0.00272	CcSEcCtD
Ezogabine—Leukopenia—Etoposide—testicular cancer	0.0011	0.00271	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00109	0.0027	CcSEcCtD
Ezogabine—Fatigue—Ifosfamide—testicular cancer	0.00109	0.0027	CcSEcCtD
Ezogabine—Infection—Cisplatin—testicular cancer	0.00109	0.00268	CcSEcCtD
Ezogabine—Constipation—Ifosfamide—testicular cancer	0.00108	0.00268	CcSEcCtD
Ezogabine—Loss of consciousness—Etoposide—testicular cancer	0.00108	0.00266	CcSEcCtD
Ezogabine—Nervous system disorder—Cisplatin—testicular cancer	0.00107	0.00265	CcSEcCtD
Ezogabine—Thrombocytopenia—Cisplatin—testicular cancer	0.00107	0.00264	CcSEcCtD
Ezogabine—Asthenia—Bleomycin—testicular cancer	0.00106	0.00263	CcSEcCtD
Ezogabine—Osteoarthritis—Doxorubicin—testicular cancer	0.00106	0.00261	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—testicular cancer	0.00106	0.00261	CcSEcCtD
Ezogabine—Hyperhidrosis—Cisplatin—testicular cancer	0.00106	0.00261	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—testicular cancer	0.00105	0.0026	CcSEcCtD
Ezogabine—Feeling abnormal—Ifosfamide—testicular cancer	0.00104	0.00258	CcSEcCtD
Ezogabine—Nausea—Vinblastine—testicular cancer	0.00104	0.00258	CcSEcCtD
Ezogabine—Discomfort—Etoposide—testicular cancer	0.00103	0.00255	CcSEcCtD
Ezogabine—Confusional state—Etoposide—testicular cancer	0.00101	0.00249	CcSEcCtD
Ezogabine—Infection—Etoposide—testicular cancer	0.000995	0.00246	CcSEcCtD
Ezogabine—Asthenia—Dactinomycin—testicular cancer	0.000993	0.00245	CcSEcCtD
Ezogabine—Influenza—Epirubicin—testicular cancer	0.000987	0.00244	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—testicular cancer	0.000987	0.00244	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—testicular cancer	0.000986	0.00244	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—testicular cancer	0.000986	0.00244	CcSEcCtD
Ezogabine—Paraesthesia—Cisplatin—testicular cancer	0.000982	0.00242	CcSEcCtD
Ezogabine—Thrombocytopenia—Etoposide—testicular cancer	0.000981	0.00242	CcSEcCtD
Ezogabine—Liver function test abnormal—Doxorubicin—testicular cancer	0.000976	0.00241	CcSEcCtD
Ezogabine—Dyspnoea—Cisplatin—testicular cancer	0.000975	0.00241	CcSEcCtD
Ezogabine—Hyperhidrosis—Etoposide—testicular cancer	0.000968	0.00239	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000944	0.00233	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—testicular cancer	0.000941	0.00232	CcSEcCtD
Ezogabine—Infestation—Methotrexate—testicular cancer	0.000941	0.00232	CcSEcCtD
Ezogabine—Rash—Bleomycin—testicular cancer	0.000936	0.00231	CcSEcCtD
Ezogabine—Dermatitis—Bleomycin—testicular cancer	0.000935	0.00231	CcSEcCtD
Ezogabine—Dysuria—Epirubicin—testicular cancer	0.000923	0.00228	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—testicular cancer	0.000923	0.00228	CcSEcCtD
Ezogabine—Dysphagia—Doxorubicin—testicular cancer	0.000913	0.00226	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—testicular cancer	0.000913	0.00226	CcSEcCtD
Ezogabine—Asthenia—Ifosfamide—testicular cancer	0.00091	0.00225	CcSEcCtD
Ezogabine—Feeling abnormal—Cisplatin—testicular cancer	0.000901	0.00223	CcSEcCtD
Ezogabine—Paraesthesia—Etoposide—testicular cancer	0.000899	0.00222	CcSEcCtD
Ezogabine—Weight increased—Epirubicin—testicular cancer	0.000898	0.00222	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—testicular cancer	0.000897	0.00222	CcSEcCtD
Ezogabine—Dyspnoea—Etoposide—testicular cancer	0.000893	0.00221	CcSEcCtD
Ezogabine—Somnolence—Etoposide—testicular cancer	0.00089	0.0022	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—testicular cancer	0.00089	0.0022	CcSEcCtD
Ezogabine—Nausea—Bleomycin—testicular cancer	0.000881	0.00218	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—testicular cancer	0.00088	0.00217	CcSEcCtD
Ezogabine—Infestation—Epirubicin—testicular cancer	0.00088	0.00217	CcSEcCtD
Ezogabine—Rash—Dactinomycin—testicular cancer	0.000873	0.00216	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000865	0.00214	CcSEcCtD
Ezogabine—Fatigue—Etoposide—testicular cancer	0.000863	0.00213	CcSEcCtD
Ezogabine—Constipation—Etoposide—testicular cancer	0.000856	0.00212	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—testicular cancer	0.000854	0.00211	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—testicular cancer	0.000854	0.00211	CcSEcCtD
Ezogabine—Haematuria—Epirubicin—testicular cancer	0.000839	0.00207	CcSEcCtD
Ezogabine—Dizziness—Ifosfamide—testicular cancer	0.000839	0.00207	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—testicular cancer	0.000834	0.00206	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—testicular cancer	0.000832	0.00206	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—testicular cancer	0.000831	0.00205	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—testicular cancer	0.000828	0.00204	CcSEcCtD
Ezogabine—Feeling abnormal—Etoposide—testicular cancer	0.000825	0.00204	CcSEcCtD
Ezogabine—Nausea—Dactinomycin—testicular cancer	0.000822	0.00203	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—testicular cancer	0.000814	0.00201	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—testicular cancer	0.000814	0.00201	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—testicular cancer	0.000814	0.00201	CcSEcCtD
Ezogabine—Rash—Ifosfamide—testicular cancer	0.0008	0.00197	CcSEcCtD
Ezogabine—Dermatitis—Ifosfamide—testicular cancer	0.000799	0.00197	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—testicular cancer	0.000789	0.00195	CcSEcCtD
Ezogabine—Asthenia—Cisplatin—testicular cancer	0.000784	0.00194	CcSEcCtD
Ezogabine—Urinary tract disorder—Epirubicin—testicular cancer	0.00078	0.00193	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—testicular cancer	0.000778	0.00192	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—testicular cancer	0.000777	0.00192	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—testicular cancer	0.000775	0.00191	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00077	0.0019	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—testicular cancer	0.000762	0.00188	CcSEcCtD
Ezogabine—Nausea—Ifosfamide—testicular cancer	0.000753	0.00186	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—testicular cancer	0.000746	0.00184	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—testicular cancer	0.00074	0.00183	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—testicular cancer	0.000738	0.00182	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—testicular cancer	0.000735	0.00182	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000722	0.00178	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—testicular cancer	0.00072	0.00178	CcSEcCtD
Ezogabine—Asthenia—Etoposide—testicular cancer	0.000719	0.00177	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—testicular cancer	0.000717	0.00177	CcSEcCtD
Ezogabine—Visual impairment—Doxorubicin—testicular cancer	0.000705	0.00174	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—testicular cancer	0.000698	0.00172	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—testicular cancer	0.000693	0.00171	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—testicular cancer	0.000692	0.00171	CcSEcCtD
Ezogabine—Rash—Cisplatin—testicular cancer	0.000689	0.0017	CcSEcCtD
Ezogabine—Dermatitis—Cisplatin—testicular cancer	0.000689	0.0017	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—testicular cancer	0.000688	0.0017	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—testicular cancer	0.000683	0.00169	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—testicular cancer	0.000682	0.00168	CcSEcCtD
Ezogabine—Malaise—Methotrexate—testicular cancer	0.000663	0.00164	CcSEcCtD
Ezogabine—Dizziness—Etoposide—testicular cancer	0.000662	0.00164	CcSEcCtD
Ezogabine—Muscle spasms—Epirubicin—testicular cancer	0.000661	0.00163	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—testicular cancer	0.00066	0.00163	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—testicular cancer	0.000658	0.00163	CcSEcCtD
Ezogabine—Nausea—Cisplatin—testicular cancer	0.000649	0.0016	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—testicular cancer	0.000648	0.0016	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—testicular cancer	0.000646	0.0016	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—testicular cancer	0.000641	0.00158	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—testicular cancer	0.000638	0.00158	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—testicular cancer	0.000636	0.00157	CcSEcCtD
Ezogabine—Rash—Etoposide—testicular cancer	0.000631	0.00156	CcSEcCtD
Ezogabine—Dermatitis—Etoposide—testicular cancer	0.000631	0.00156	CcSEcCtD
Ezogabine—Malaise—Epirubicin—testicular cancer	0.00062	0.00153	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—testicular cancer	0.000618	0.00153	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—testicular cancer	0.000618	0.00153	CcSEcCtD
Ezogabine—Syncope—Epirubicin—testicular cancer	0.000617	0.00152	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—testicular cancer	0.000616	0.00152	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—testicular cancer	0.000612	0.00151	CcSEcCtD
Ezogabine—Confusional state—Methotrexate—testicular cancer	0.000605	0.00149	CcSEcCtD
Ezogabine—Loss of consciousness—Epirubicin—testicular cancer	0.000605	0.00149	CcSEcCtD
Ezogabine—Vision blurred—Doxorubicin—testicular cancer	0.0006	0.00148	CcSEcCtD
Ezogabine—Infection—Methotrexate—testicular cancer	0.000596	0.00147	CcSEcCtD
Ezogabine—Nausea—Etoposide—testicular cancer	0.000595	0.00147	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000591	0.00146	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—testicular cancer	0.000588	0.00145	CcSEcCtD
Ezogabine—Thrombocytopenia—Methotrexate—testicular cancer	0.000587	0.00145	CcSEcCtD
Ezogabine—Anxiety—Epirubicin—testicular cancer	0.000584	0.00144	CcSEcCtD
Ezogabine—Hyperhidrosis—Methotrexate—testicular cancer	0.00058	0.00143	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—testicular cancer	0.000579	0.00143	CcSEcCtD
Ezogabine—Malaise—Doxorubicin—testicular cancer	0.000574	0.00142	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—testicular cancer	0.000573	0.00141	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—testicular cancer	0.000572	0.00141	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—testicular cancer	0.000571	0.00141	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—testicular cancer	0.00057	0.00141	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—testicular cancer	0.000566	0.0014	CcSEcCtD
Ezogabine—Loss of consciousness—Doxorubicin—testicular cancer	0.000559	0.00138	CcSEcCtD
Ezogabine—Infection—Epirubicin—testicular cancer	0.000558	0.00138	CcSEcCtD
Ezogabine—Shock—Epirubicin—testicular cancer	0.000552	0.00136	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—testicular cancer	0.000551	0.00136	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—testicular cancer	0.00055	0.00136	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—testicular cancer	0.000543	0.00134	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—testicular cancer	0.00054	0.00133	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—testicular cancer	0.000539	0.00133	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—testicular cancer	0.000535	0.00132	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—testicular cancer	0.000535	0.00132	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—testicular cancer	0.000533	0.00132	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—testicular cancer	0.00053	0.00131	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—testicular cancer	0.000528	0.0013	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—testicular cancer	0.000524	0.00129	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000518	0.00128	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—testicular cancer	0.000517	0.00128	CcSEcCtD
Ezogabine—Infection—Doxorubicin—testicular cancer	0.000516	0.00127	CcSEcCtD
Ezogabine—Shock—Doxorubicin—testicular cancer	0.000511	0.00126	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—testicular cancer	0.000509	0.00126	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000509	0.00126	CcSEcCtD
Ezogabine—Paraesthesia—Epirubicin—testicular cancer	0.000504	0.00125	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000502	0.00124	CcSEcCtD
Ezogabine—Dyspnoea—Epirubicin—testicular cancer	0.000501	0.00124	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—testicular cancer	0.000499	0.00123	CcSEcCtD
Ezogabine—Feeling abnormal—Methotrexate—testicular cancer	0.000494	0.00122	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—testicular cancer	0.000494	0.00122	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000485	0.0012	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—testicular cancer	0.000484	0.0012	CcSEcCtD
Ezogabine—Constipation—Epirubicin—testicular cancer	0.00048	0.00119	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—testicular cancer	0.000466	0.00115	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—testicular cancer	0.000463	0.00114	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—testicular cancer	0.000463	0.00114	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—testicular cancer	0.000462	0.00114	CcSEcCtD
Ezogabine—Dyspepsia—Doxorubicin—testicular cancer	0.000457	0.00113	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000448	0.00111	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—testicular cancer	0.000448	0.00111	CcSEcCtD
Ezogabine—Constipation—Doxorubicin—testicular cancer	0.000444	0.0011	CcSEcCtD
Ezogabine—Asthenia—Methotrexate—testicular cancer	0.00043	0.00106	CcSEcCtD
Ezogabine—Feeling abnormal—Doxorubicin—testicular cancer	0.000428	0.00106	CcSEcCtD
Ezogabine—Asthenia—Epirubicin—testicular cancer	0.000403	0.000995	CcSEcCtD
Ezogabine—Dizziness—Methotrexate—testicular cancer	0.000397	0.00098	CcSEcCtD
Ezogabine—Rash—Methotrexate—testicular cancer	0.000378	0.000934	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—testicular cancer	0.000378	0.000933	CcSEcCtD
Ezogabine—Asthenia—Doxorubicin—testicular cancer	0.000373	0.000921	CcSEcCtD
Ezogabine—Dizziness—Epirubicin—testicular cancer	0.000371	0.000917	CcSEcCtD
Ezogabine—Nausea—Methotrexate—testicular cancer	0.000356	0.00088	CcSEcCtD
Ezogabine—Rash—Epirubicin—testicular cancer	0.000354	0.000874	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—testicular cancer	0.000354	0.000873	CcSEcCtD
Ezogabine—Dizziness—Doxorubicin—testicular cancer	0.000344	0.000848	CcSEcCtD
Ezogabine—Nausea—Epirubicin—testicular cancer	0.000333	0.000824	CcSEcCtD
Ezogabine—Rash—Doxorubicin—testicular cancer	0.000328	0.000809	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—testicular cancer	0.000327	0.000808	CcSEcCtD
Ezogabine—Nausea—Doxorubicin—testicular cancer	0.000309	0.000762	CcSEcCtD
